Skip to content

13F-HR filed by Vivo Capital, LLC

Vivo Capital, LLC filed this 13F-HR for the quarter ended 2016-12-31, filed 2017-02-15, with 24 holding rows worth $300,435,000.

Accession
0001214659-17-001184
Filed
2017-02-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2016

A holdings report, 24 entries on the cover page, a total value of $300,435,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $300,435,000 with VALUE read as thousands by filing date, 13F file number 028-17467. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ACLARIS THERAPEUTICS INC COM00461U105Stock3,283,569$89,116,000thousands by filing date
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR1,766,832$35,761,000thousands by filing date
CODEXIS INC192005106COM5,294,825$24,356,000thousands by filing date
NABRIVA THERAPEUTICS AG62957M104SPONSORED ADR4,021,559$23,968,000thousands by filing date
EIGER BIOPHARMACEUTICALS INC28249U105COM1,787,091$20,820,000thousands by filing date
AIMMUNE THERAPEUTICS INC.00900T107Common Stock763,009$15,604,000thousands by filing date
ADVANCED ACCELERATOR APPLIC SPONSORED ADS00790T100ADR455,798$12,197,000thousands by filing date
TREVENA INC89532E109COM1,728,000$10,161,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS855,000$9,491,000thousands by filing date
REGENXBIO INC75901B107COM502,863$9,328,000thousands by filing date
AGILE THERAPEUTICS INC00847L100COM1,513,975$8,630,000thousands by filing date
COLUCID PHARMACEUTICALS INC19716T101COM225,000$8,190,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD3,000,000$7,200,000thousands by filing date
Capnia, Inc.14066L105Common7,456,984$6,040,000thousands by filing date
BIOPHARMX CORP09072X101COM12,814,286$4,793,000thousands by filing date
AKARI THERAPEUTICS PLC00972G108ADR527,842$3,716,000thousands by filing date
Sierra Oncology, Inc.74346L101common2,438,270$3,633,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM300,325$2,123,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM500,000$1,810,000thousands by filing date
REVANCE THERAPEUTICS INC761330109COM77,373$1,602,000thousands by filing date
DYNAVAX TECHNOLOGIES CORP268158201COM NEW359,828$1,421,000thousands by filing date
OCERA THERAPEUTICS INC COM67552A108COM153,331$322,000thousands by filing date
Adobe Systems Inc98979H103COM98,515$77,000thousands by filing date
CAPNIA INC14066L113*W EXP 11/12/201943,858$76,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-17-001184this filing2017-02-15acceptance time not in the bulk data set
13F-HR/A 0001214659-17-002413 base2017-04-06acceptance time not in the bulk data set